Skip to content
mapperlab
← Dashboard
Stock

ENOV

Enovis CORP
Health CareHealth Care EquipmentLatest close $254 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
4
27 funds tracked
Ever held
9
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

Aug 11, 2022Nov 13, 2024Aug 13, 2025May 15, 2026
Now
5

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Bridgewater Associates re-entered$59$25-57%
Citadel Advisors$43$25-41%
D.E. Shaw re-entered$43$25-41%
AQR Capital Management$43$25-41%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Point72 Asset Management→ $22-51%
Renaissance Technologies 2× in & out→ $31+4%
Millennium Management 2× in & out—+0%
Two Sigma Investments→ $44-4%
Maverick Capital→ $43-18%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Enovis CORP. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
12
Filings · last 90d
31
Total on file
609
Recent SEC buffer
Most recent
Jun 3, 2026

30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 609 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Enovis CORP

Annual figures sourced directly from Enovis CORP's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$2.25B
FY2025+7% YoY
Net income
-$1.18B
FY2025-43% YoY
EPS (diluted)
$-20.75
FY2025-39% YoY
Free cash flow(?)
$19.92M
FY2025+130% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Enovis CORP — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Bridgewater AssociatesQ2 2026open$24$22-10%
D.E. ShawQ4 2025open$30$25-16%
Renaissance TechnologiesQ3 2025Q4 2025$30$31+4%
Millennium ManagementQ1 2025Q2 2025$0.00—+0%
Point72 Asset ManagementQ1 2025Q1 2026$44$22-51%
Two Sigma InvestmentsQ4 2024Q1 2025$46$44-4%
Citadel AdvisorsQ3 2024open$43$25-41%
D.E. ShawQ3 2024Q2 2025$43$36-17%
AQR Capital ManagementQ3 2024open$43$25-41%
Millennium ManagementQ3 2024open$43$25-41%
Renaissance TechnologiesQ3 2024Q4 2024$43$46+7%
Maverick CapitalQ2 2024Q3 2024$53$43-18%
Bridgewater AssociatesQ3 2022Q2 2025$59$36-38%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.